

Vascular Endothelial Growth Factor (VEGF) Inhibitors for Ophthalmic Use

BENEFIT APPLICATION

Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations or exceptions may apply. Benefits may vary based on contract, and individual member benefits must be verified. Wellmark determines medical necessity only if the benefit exists and no contract exclusions are applicable. This policy may not apply to FEP. Benefits are determined by the Federal Employee Program.

DESCRIPTION

The intent of the vascular endothelial growth factor (VEGF) inhibitor drug policy is to ensure appropriate selection of patients for therapy based on product labeling, clinical guidelines and clinical studies. This policy informs prescribers of preferred products, Byooviz, Eylea, Eylea HD, Lucentis, and Vabysmo, and provides an exception process for non-preferred products, Beovu, Cimerli, Pavblu, and Susvimo, through prior authorization. Coverage for non-preferred products is provided based on clinical circumstances that would exclude the use of the preferred product and may be based on previous use of a product. The coverage review process will ascertain situations where a clinical exception can be made.

Note:

- Bevacizumab is considered medically necessary for the treatment of choroidal and retinal vascular disorders addressed within this policy and does not require prior authorization.
- Lucentis (ranibizumab), Byooviz (ranibizumab-nuna), Eylea (aflibercept), Eylea HD (aflibercept), and Vabysmo (faricimab) do not require prior authorization.

Eylea® (aflibercept) is approved by the Food and Drug Administration (FDA) for the following indications:

- Neovascular (wet) age-related macular degeneration (AMD)
- Macular edema following retinal vein occlusion (RVO)
- Diabetic macular edema (DME)
- Diabetic retinopathy (DR)
- Retinopathy of Prematurity (ROP)

Compensatory use:

- Macular choroidal neovascularization (mCNV)

Eylea HD® (aflibercept) is approved by the Food and Drug Administration (FDA) for the following indications:

- Neovascular (wet) age-related macular degeneration (AMD)
- Diabetic macular edema (DME)
- Diabetic retinopathy (DR)
- Macular edema following retinal vein occlusion (RVO)

Lucentis® (ranibizumab) is approved by the FDA for the following indications:

- Neovascular (wet) age-related macular degeneration (AMD)
- Diabetic macular edema (DME)
- Diabetic retinopathy (DR)
- Macular edema following retinal vein occlusion (RVO)
- Myopic choroidal neovascularization (mCNV)

Byooviz™ (ranibizumab-nuna), a biosimilar to Lucentis®, is approved by the FDA for the following indications:

- Neovascular (wet) age-related macular degeneration (AMD)
- Macular edema following retinal vein occlusion (RVO)
- Myopic choroidal neovascularization (mCNV)

Cimerli™ (ranibizumab-eqrn), a biosimilar to Lucentis®, is approved by the FDA for the following indications:

- Neovascular (wet) age-related macular degeneration (AMD)
- Macular edema following retinal vein occlusion (RVO)
- Diabetic Macular Edema (DME)
- Diabetic Retinopathy (DR)
- Myopic choroidal neovascularization (mCNV)

Beovu® (brolucizumab-dbil) is approved by the FDA for the following indications:

- Neovascular (wet) age-related macular degeneration (AMD)
- Diabetic macular edema (DME)

Vabysmo® (faricimab-svoa) is approved by the FDA for the following indications:

- Neovascular (wet) age-related macular degeneration (AMD)
- Diabetic macular edema (DME)
- Macular edema following retinal vein occlusion (RVO)

Susvimo™ (ranibizumab) is approved by the FDA for the following indications:

- Neovascular (wet) age-related macular degeneration (AMD) in patients who have previously responded to at least two intravitreal injections of a Vascular Endothelial Growth Factor (VEGF) inhibitor.
- Diabetic Macular Edema (DME) in patients who have previously responded to at least two intravitreal injections of a Vascular Endothelial Growth Factor (VEGF) inhibitor.
- Diabetic Retinopathy (DR) in patients who have previously responded to at least two intravitreal injections of a Vascular Endothelial Growth Factor (VEGF) inhibitor.

Pavblu™ (aflibercept-ayyh) is approved by the FDA for the following indications:

- Neovascular (wet) age-related macular degeneration (AMD)
- Macular edema following retinal vein occlusion (RVO)
- Diabetic Macular Edema (DME)
- Diabetic Retinopathy (DR)

Bevacizumab

While not FDA approved for ophthalmic use, **bevacizumab** has the support of peer reviewed literature and is considered **medically necessary** for the treatment of choroidal and retinal vascular disorders addressed within this policy.

Table. Vascular Endothelial Growth Factor (VEGF) Inhibitor Products

Medication	Generic Name
Preferred Products:	
Byooviz™	ranibizumab-nuna
Lucentis®	ranibizumab
Vabysmo®	faricimab-svoa
Eylea®	aflibercept
Eylea® HD	
Targeted Products:	
Beovu®	brolocizumab-dbli
Cimerli™	ranibizumab-eqrn
Susvimo™	ranibizumab
Pavblu™	aflibercept-ayyh
POLICY	

***Bevacizumab** is the best value VEGF inhibitor for the treatment of choroidal and retinal vascular disorders addressed within this policy, has the support of peer reviewed literature, and DOES NOT require review or prior authorization.

****Lucentis (ranibizumab), Eylea (aflibercept), Eylea HD (aflibercept), Byooviz (ranibizumab-nuna) and Vabysmo (faricimab)** do not require prior authorization and will be considered medically necessary for the treatment of the following:

- Neovascular (wet) AMD
- Macular edema following RVO (both BRVO and CRVO)
- Diabetic macular edema
- Proliferative diabetic retinopathy as an adjunct to photocoagulation or vitrectomy
- Retinopathy of Prematurity (ROP)
- Diabetic retinopathy
- Choroidal neovascularization secondary to:
 - Angioid streaks
 - Central serous chorioretinopathy
 - Choroidal rupture or trauma
 - Multifocal choroiditis
 - Pathologic myopia
 - Presumed ocular histoplasmosis syndrome
 - Uveitis
 - Idiopathic choroidal neovascularization

Required Documentation

- I. Submission of the following information is necessary to initiate the prior authorization review for the non-preferred products, Beovu, Cimerli, Pavblu, and Susvimo:

- Chart notes documenting inadequate response to or an intolerable adverse event to the preferred products, Byooviz, Lucentis, Eylea, Eylea HD, and Vabysmo, for an indication for which the preferred products have been FDA approved or have a compendial use for.

Preferred Drug Plan Design

Member must meet BOTH the Preferred Drug Plan Design and the Criteria for Initial Approval/Continuation of Therapy when both are applicable.

- I. Criteria for initial approval for the non-preferred products will only apply when at least ONE of the following criteria are met:
 - Member has had a documented inadequate response or intolerable adverse event to one of the preferred products.
 - Member is currently receiving therapy with **a non-preferred product**, excluding when **the non-preferred product** is obtained as samples or via manufacturer's patient assistance programs, and is experiencing a positive therapeutic outcome.

- II. A series of intravitreal injections with **Cimerli (ranibizumab-eqrn)** may be considered **medically necessary** for the treatment of the following:
 - Neovascular (wet) AMD
 - Macular edema following RVO (both BRVO and CRVO)
 - Diabetic macular edema
 - Proliferative diabetic retinopathy as an adjunct to photocoagulation or vitrectomy
 - Diabetic retinopathy
 - Choroidal neovascularization secondary to:
 - Angioid streaks
 - Central serous chorioretinopathy
 - Choroidal rupture or trauma
 - Multifocal choroiditis
 - Pathologic myopia
 - Presumed ocular histoplasmosis syndrome
 - Uveitis
 - Idiopathic choroidal neovascularization

- III. A series of intravitreal injections with **Beovu (brolucizumab-dblI)** may be considered **medically necessary** for the treatment of neovascular (wet) AMD and diabetic macular edema.

- III. A series of intravitreal injections with **Susvimo™ (ranibizumab)** may be considered **medically necessary** when all of the following criteria are met:
 - Member meets either of the following:
 - Member has a diagnosis of neovascular (wet) age-related macular degeneration
 - Member has a diagnosis of diabetic macular edema
 - Member has a diagnosis of diabetic retinopathy
 - Member has previously responded to at least two intravitreal injections of a Vascular Endothelial Growth Factor (VEGF) inhibitor (e.g., Byooviz, Lucentis) within the past 6 months.
 - Must be used in conjunction with the Susvimo ocular implant.

- IV. A series of intravitreal injections with **Pavblu (aflibercept-ayyh)** may be considered **medically necessary** for the treatment of the following:
 - Neovascular (wet) AMD
 - Macular edema following RVO (both BRVO and CRVO)
 - Diabetic macular edema

- Diabetic retinopathy

Approval is for 6 months.

Continuation of Therapy

Authorization of 12 months may be granted for continued treatment of an indication listed in Criteria for Initial Approval above for members who have demonstrated a positive clinical response to therapy (e.g., improvement or maintenance in best corrected visual acuity [BCVA] or visual field, or a reduction in the rate of vision decline or the risk of more severe vision loss).

PROCEDURES AND BILLING CODES

To report provider services, use appropriate CPT* codes, Alpha Numeric (HCPCS level 2) codes, Revenue codes, and/or ICD-CM diagnostic codes.

- Code(s), if applicable.
 - C9161 – Injection, aflibercept hd, 1 mg (cancelled 3-31-2024)
 - C9097 – Injection, faricimab-svoa, 0.1 mg (deleted 10-1-2022)
 - C9399 – Unclassified drugs or biologicals
 - J0177 – Injection, aflibercept hd, 1 mg (effective 4-1-2024)
 - J0178 – Injection, aflibercept, 1 mg
 - J0179 – Injection, brolucizumab, 1 mg
 - J2777 – Injection, faricimab-svoa, 0.1 mg (effective 10-1-2022)
 - J2778 – Injection, ranibizumab, 0.1 mg
 - J2779 – Injection, ranibizumab, via sustained release intravitreal implant (susvimo), 0.1 mg (effective 7/1/2022)
 - J3490 – Unclassified drugs
 - J3590 – Unclassified biologicals
 - Q5124 Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg
 - Q5128 – Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg
 - Q5147 – Injection, aflibercept-ayyh (pavblu), biosimilar, 1 mg (effective 4-1-2025)

REFERENCES

- Eylea [prescribing information]. Regeneron Pharmaceuticals, Inc. Tarrytown NY, February 2023.
- Eylea HD [prescribing information]. Regeneron Pharmaceuticals, Inc. Tarrytown NY, November 2025.
- Lucentis [prescribing information]. Genentech, Inc. South San Francisco CA, November 2019.
- Beovu [prescribing information]. Novartis Pharmaceuticals Corporation. East Hanover, NJ, May 2022.
- Byooviz [prescribing information]. Biogen Inc. Cambridge, MA, September 2021.
- Susvimo. [package insert]. San Francisco, CA: Genentech, Inc.; May 2025.
- Vabysmo [package insert]. South San Francisco, CA: Genentech, Inc.; October 2023.
- Cimerli [package insert]. Redwood City, CA: Coherus BioSciences, Inc.; August 2022.
- Pavblu [package insert]. Thousand Oaks, CA: Amgen, Inc.; August 2024.
- Martin DF, Maguire MG, Fine SL, et al, and the Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. *Ophthalmology* 2012; 119:1388-1398.
- Martin DF, Maguire MG, Ying GS, et al, and the CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. *N Engl J Med* 2011; 364:1897-1908.
- Chakravarthy U, Harding SP, Rogers CA, et al, on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age-related choroidal neovascularization: 2-year findings of the IVAN

randomised controlled trial. *Lancet* Published online July 19, 2013. [http://dx.doi.org/10.1016/S0140-6736\(13\)61501-9](http://dx.doi.org/10.1016/S0140-6736(13)61501-9).

- Cheung LK, Eaton A. Review of therapeutics: age-related macular degeneration. *Pharmacotherapy* 2013;33(8):838-855.
- Evoy KE, Abel SR. Ranibizumab: the first vascular endothelial growth factor inhibitor approved for the treatment of diabetic macular edema. *Ann Pharmacother* 2013;47:811-818.
- Stein JD, Newman-Casey PA, Kim DD, Nwanyanwu KH, Johnson MW, Hutton DW. Cost-effectiveness of various interventions for newly diagnosed diabetic macular edema. *Ophthalmology* 2013;120(9):1835-1842.
- Rajendram R, Fraser-Bell A, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema 24-month data: report 3. *Arch Ophthalmol* 2012;130:972-979.
- Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: early treatment diabetic retinopathy study report number I. *Arch Ophthalmol* 1985; 103: 1796-1806.
- Arevalo JF, Sanchez JG, Fromow-Guerra J, et al. PanAmerican Collaborative Retina Study Group (PACORES). Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the PanAmerican Collaborative Retina Study Group (PACORES) at 12-month follow-up. *Arch Clin Exp Ophthalmol* 2009;247:735-743.
- Campochiaro PA, Heier JS, Fomer I, et al. BRAVO Investigators. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. *Ophthalmology* 2010;117(6):1102-1112.
- Brown DM, Campochiaro PA, Singh RP, et al. CRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. *Ophthalmology* 2010;117(6):1124-1133.
- Brown DM, Heier JS, Clark WL, et al. COPERNICUS Investigators. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1 year results for phase 3 COPERNICUS study. *Am J Ophthalmol* 2013;155:429-437.
- GALILEO
- Epstein DL, Algvere PV, von Wendt G, Seregard S, Kvanta A. Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study. *Ophthalmology* 2012;119:2587-2591.
- Epstein DL, Algvere PV, von Wendt G, et al. Bevacizumab for macular edema in central retinal vein occlusion: a prospective randomized double masked clinical study. *Ophthalmology* 2012;119:1184-1189.
- Cionni DA, Lewis SA, Petersen MR, et al. Analysis of outcomes for intravitreal bevacizumab in the treatment of choroidal neovascularization secondary to ocular histoplasmosis. *Ophthalmology* 2012; 119:327-332.
- Evoy KE, Abel SR. Aflibercept: newly approved for the treatment of macular edema following central retinal vein occlusion. *Ann Pharmacother* 2013;47:819-827.
- American Academy of Ophthalmology Retinal/Vitreous Panel. Preferred Practice Pattern® Guidelines. Age-Related Macular Degeneration. San Francisco, CA: American Academy of Ophthalmology; 2019. Available at: <https://www.aao.org/preferred-practice-pattern/age-related-macular-degeneration-ppp>.
- American Academy of Ophthalmology Retinal/Vitreous Panel. Preferred Practice Pattern® Guidelines. Diabetic Retinopathy. San Francisco, CA: American Academy of Ophthalmology; 2019. Available at: <https://www.aao.org/preferred-practice-pattern/diabetic-retinopathy-ppp>.
- American Academy of Ophthalmology Retinal/Vitreous Panel. Preferred Practice Pattern® Guidelines. Retinal Vein Occlusions. San Francisco, CA: American Academy of Ophthalmology; 2019. Available at: <https://www.aao.org/preferred-practice-pattern/retinal-vein-occlusions-ppp>.

POLICY HISTORY

Policy #: 09.03.12

Policy Creation: November 2014

Reviewed: October 2025

Revised: October 2025

Current Effective Date: January 1, 2026